Organoruthenium 9E1 and APL Altered Collagen II263-272 Peptide as Therapy for Autoimmune Diseases
DOI:
https://doi.org/10.59653/jhsmt.v1i02.277Keywords:
9E1, APL, autoimmune, EAE, collagen-induced arthritisAbstract
Therapy for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis (MS) is currently available in symptom management, pain-relieving, and mitigation of disease. Currently, prescribed drugs for patients with the disease work in specific mechanisms, regardless of failure to determine the most effective medication. We use a literature review to highlight two newly examined substances: organoruthenium 9E1 and APL altered collagen II263-272 peptide, and elaborate substances mentioned above' potential to be used in rheumatoid arthritis and MS therapy. Several studies show positive effects from 9E1 and altered CII263-272 peptides on experimented mice. Altered CII263-272 peptide can elicit Th cells to produce neurotrophic factors, decrease the body amount of pro-inflammatory T cells, increase the body amount of anti-inflammatory T cells, and alleviate collagen-induced arthritis symptoms. Meanwhile, 9E1 can inhibit Mst1 kinase effectively (IC50=45nM), giving consequences of decreasing Th1 cells' cytokines, increasing Th2 cells' cytokines, decreasing body amount's IgG1 and IgG2a, slowing down EAE and collagen-induced arthritis' manifestation, increasing IL-10 and IL-4-producing T cells. Organoruthenium and altered CII263-272 peptide possess positive and multiple effects as therapies for EAE and collagen-induced arthritis, hence potential to be prescribed to patients with rheumatoid arthritis and MS. This literature review suggests further research concerning 9E1 and altered CII263-272 peptide usage in the community to examine their effectivity, side effects, and suitable dose.
Downloads
References
Anand, R., Maksimoska, J., Pagano, N., Wong, E. Y., Gimotty, P. A., Diamond, S. L., Meggers, E., & Marmorstein, R. (2009). Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor. Journal of Medicinal Chemistry, 52(6). https://doi.org/10.1021/jm8005806
Anderton, S. M. (2001). Peptide-based immunotherapy of autoimmunity: A path of puzzles, paradoxes and possibilities. In Immunology (Vol. 104, Issue 4). https://doi.org/10.1046/j.1365-2567.2001.01324.x
Centers for Disease Control and Prevention (CDC). (2009). Prevalence and most common causes of disability among adults--United States, 2005. MMWR. Morbidity and Mortality Weekly Report, 58(16).
Constantinescu, C. S., Farooqi, N., O’Brien, K., & Gran, B. (2011). Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). In British Journal of Pharmacology (Vol. 164, Issue 4). https://doi.org/10.1111/j.1476-5381.2011.01302.x
Darmawan, J., Muirden, K. D., Valkenburg, H. A., & Wigley, R. D. (1993). The epidemiology of rheumatoid arthritis in Indonesia. Rheumatology, 32(7). https://doi.org/10.1093/rheumatology/32.7.537
Elkhalifa, S., Anwar, S., & Karim, Y. (2018). Autoimmune Disease: Treatment. In Encyclopedia of Life Sciences. https://doi.org/10.1002/9780470015902.a0001437.pub3
Fugger, L., Jensen, L. T., & Rossjohn, J. (2020). Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. In Cell (Vol. 181, Issue 1). https://doi.org/10.1016/j.cell.2020.03.007
Klöß, S., Dehmel, S., Braun, A., Parnham, M. J., Köhl, U., & Schiffmann, S. (2020). From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. In Frontiers in Immunology (Vol. 11). https://doi.org/10.3389/fimmu.2020.01423
Krabbe, K. S., Nielsen, A. R., Krogh-Madsen, R., Plomgaard, P., Rasmussen, P., Erikstrup, C., Fischer, C. P., Lindegaard, B., Petersen, A. M., Taudorf, S., Secher, N. H., Pilegaard, H., Bruunsgaard, H., & Pedersen, B. K. (2007). Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia, 50(2). https://doi.org/10.1007/s00125-006-0537-4
Li, C., Bi, Y., Li, Y., Yang, H., Yu, Q., Wang, J., Wang, Y., Su, H., Jia, A., Hu, Y., Han, L., Zhang, J., Li, S., Tao, W., & Liu, G. (2017). Dendritic cell MST1 inhibits Th17 differentiation. Nature Communications, 8. https://doi.org/10.1038/ncomms14275
Li, R., Li, X., & Li, Z. (2009). Altered collagen II 263-272 peptide immunization induces inhibition of collagen-induced arthritis through a shift toward Th2-type response. Tissue Antigens, 73(4). https://doi.org/10.1111/j.1399-0039.2009.01223.x
Naegelin, Y., Saeuberli, K., Schaedelin, S., Dingsdale, H., Magon, S., Baranzini, S., Amann, M., Parmar, K., Tsagkas, C., Calabrese, P., Penner, I. K., Kappos, L., & Barde, Y. A. (2020). Levels of brain-derived neurotrophic factor in patients with multiple sclerosis. Annals of Clinical and Translational Neurology, 7(11). https://doi.org/10.1002/acn3.51215
Praskova, M., Xia, F., & Avruch, J. (2008). MOBKL1A/MOBKL1B Phosphorylation by MST1 and MST2 Inhibits Cell Proliferation. Current Biology, 18(5). https://doi.org/10.1016/j.cub.2008.02.006
Pul, R., Moharregh-Khiabani, D., Škuljec, J., Skripuletz, T., Garde, N., Voß, E. V., & Stangel, M. (2011). Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity. Journal of Neuroimmune Pharmacology, 6(3). https://doi.org/10.1007/s11481-010-9248-1
Rocamora-Reverte, L., Melzer, F. L., Würzner, R., & Weinberger, B. (2021). The Complex Role of Regulatory T Cells in Immunity and Aging. In Frontiers in Immunology (Vol. 11). https://doi.org/10.3389/fimmu.2020.616949
Sabatos-Peyton, C. A., Verhagen, J., & Wraith, D. C. (2010). Antigen-specific immunotherapy of autoimmune and allergic diseases. In Current Opinion in Immunology (Vol. 22, Issue 5). https://doi.org/10.1016/j.coi.2010.08.006
Salojin, K. V., Hamman, B. D., Chang, W. C., Jhaver, K. G., Al-Shami, A., Crisostomo, J., Wilkins, C., Digeorge-Foushee, A. M., Allen, J., Patel, N., Gopinathan, S., Zhou, J., Nouraldeen, A., Jessop, T. C., Bagdanoff, J. T., Augeri, D. J., Read, R., Vogel, P., Swaffield, J., … Oravecz, T. (2014). Genetic deletion of Mst1 alters T cell function and protects against autoimmunity. PLoS ONE, 9(5). https://doi.org/10.1371/journal.pone.0098151
Skaper, S. (2008). The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors. CNS & Neurological Disorders - Drug Targets, 7(1). https://doi.org/10.2174/187152708783885174
Skaper, S. D. (2012). The neurotrophin family of neurotrophic factors: An Overview. In Methods in Molecular Biology (Vol. 846). https://doi.org/10.1007/978-1-61779-536-7_1
Tomiyama, T., Ueda, Y., Katakai, T., Kondo, N., Okazaki, K., & Kinashi, T. (2013). Antigen-Specific Suppression and Immunological Synapse Formation by Regulatory T Cells Require the Mst1 Kinase. PLoS ONE, 8(9). https://doi.org/10.1371/journal.pone.0073874
Williams, R. O. (2004). Collagen-induced arthritis as a model for rheumatoid arthritis. Methods in Molecular Medicine, 98. https://doi.org/10.1385/1-59259-771-8:207
Zhang, J., Hu, X., Dong, X., Chen, W., Zhang, L., Chang, Y., Wu, Y., & Wei, W. (2020). Regulation of T Cell Activities in Rheumatoid Arthritis by the Novel Fusion Protein IgD-Fc-Ig. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.00755
Zhao, J., Li, R., He, J., Shi, J., Long, L., & Li, Z. (2008). Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells. Rheumatology International, 29(1). https://doi.org/10.1007/s00296-008-0634-4
Ziemssen, T., Kümpfel, T., Klinkert, W. E. F., Neuhaus, O., & Hohlfeld, R. (2002). Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy. Brain, 125(11). https://doi.org/10.1093/brain/awf252
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Khairu Zein Safruddin, Ardhin Martdana, Fenska Seipalla, Tirza Sosanta
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
